首页 > 市场调查报告书 > 製药

癌症分子标靶治疗学

市场调查报告书

商品编码

1815336

标靶放射性药物市场报告：2031 年趋势、预测与竞争分析

Targeted Radiopharmaceutical Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年09月12日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

全球标靶放射性药物市场前景光明，标靶治疗和标靶诊断市场蕴藏着巨大机会。预计2025年至2031年，全球标靶放射性药物市场将以14.4%的复合年增长率成长。癌症和心血管疾病发生率的上升以及人口老化是推动该市场成长的关键因素。

Lucintel 预测，利用放射性物质选择性地瞄准和治疗癌细胞和其他患病组织的标靶治疗将在预测期内实现高速增长。
从应用角度来看，标靶治疗有望因前列腺癌、神经内分泌肿瘤和淋巴瘤的有效治疗而实现高速成长。
按地区划分，预计北美将在预测期内实现最高成长。

靶向放射性药物市场的新趋势

靶向放射性药物市场受到多种新兴趋势的影响，这些趋势将决定其未来的成长。这些趋势包括技术进步、监管变化以及个人化医疗日益增长的重要性。随着产业的不断发展，这些趋势不仅会影响治疗效果，还会影响新产品的上市方式以及与医疗保健系统的整合。

治疗诊断学日益受到关注：治疗诊断学结合了诊断和治疗放射性药物，是一个快速发展的趋势。这种方法能够利用放射性同位素精准靶向癌细胞，从而製定个人化治疗方案。同时诊断和治疗可提高疗效并减少副作用。这一趋势在肿瘤学领域尤为明显，用于前列腺癌的Pluvicto和镥-177等放射性药物既用于成像，也用于治疗，推动了市场的显着增长。
人工智慧与机器学习的融合：人工智慧和机器学习正日益应用于放射性药物的开发。这些技术透过预测放射性药物的疗效和毒性特征，帮助优化其设计。人工智慧工具也正在简化放射性药物的生产流程，降低成本并提高准确性。这种融合在确定最佳剂量和患者特异性治疗方法尤其有用，最终将推动个人化医疗的发展，并减少放射治疗相关的副作用。
标靶治疗的扩展：癌症仍是标靶放射性药物的主要治疗目标，许多研发成果旨在改善治疗效果。由于用于治疗神经内分泌肿瘤等难治性癌症的放射性药物数量不断增加，标靶癌症治疗市场正在不断扩大。诸如α粒子疗法之类的技术创新，能够将辐射更局部地输送到癌细胞，正日益受到关注。癌症发生率的上升以及对更有效、微创治疗的需求不断增长，推动了靶向放射性药物市场的发展，使其成为癌症治疗的重要工具。
监管进展和核准流程：监管机构，尤其是美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA)，正在简化放射性药物的核准流程，以促进新疗法更快进入市场。例如，美国食品药物管理局 (FDA) 正在为放射性药物的核准提供更灵活的途径，以加速救命疗法的审批流程。这一趋势不仅缩短了从研究到患者用药的时间，也鼓励了放射性药物设计的创新。预计更强有力的监管支持将增强市场信心，并进一步推动这些疗法在全球范围内的应用。
全球合作与研究倡议：放射性药物的开发由各国和各研究机构之间的合作所推动。大学、生技公司和医疗保健组织之间的官民合作关係关係正在加速创新。国际研究联盟正在开发新的同位素，改进生产技术，并更好地了解放射性药物在不同患者群体中的有效性。这种全球合作模式正在培育更多样化的放射性药物产品线，确保世界各地的患者都能从尖端治疗中受益。

这些趋势正在重塑针对放射性药物市场，推动创新，改善患者疗效，并降低治疗成本。人工智慧、监管进步和全球合作的融合正在加速标靶治疗的开发和普及，尤其是在肿瘤领域。随着市场的成长，这些趋势将继续优化个人化、精准治疗的交付，最终改变癌症和其他复杂疾病的医疗保健模式。

靶向放射性药物市场的最新发展

从监管突破到技术创新，近期的几大趋势正在改变标靶放射性药物市场。这些发展正在提高放射性药物治疗的精准度、可用性和疗效，为改善患者治疗效果和促进市场成长铺平道路。

FDA核准Pluvicto：Pluvicto (177Lu-PSMA-617) 用于治疗摄护腺癌，核准标靶放射性药物在肿瘤治疗领域的重大里程碑。这种新型疗法将放射性粒子与特异性靶向前列腺癌细胞的分子结合，从而减少对健康组织的损害。 FDA核准是前列腺癌领域首个此类药物，为晚期癌患者带来了新的希望。这项进展为癌症治疗的进一步创新打开了大门，尤其是针对具有特定分子标靶的癌症。
阿尔法粒子疗法的发展：阿尔法粒子疗法，例如锕-225和镭-223，已成为治疗多种癌症的有前景的疗法。这些疗法能够提供高度局部的辐射，最大限度地减少对周围健康组织的损伤，并代表了一种治疗对传统疗法抗药性的肿瘤的新方法。随着阿尔法粒子疗法研究的不断发展，靶向放射性药物市场预计将出现显着增长，尤其是在转移性癌症的治疗方面。
影像和诊断技术的进步：PET 和 SPECT 等分子成像技术的进步显着提高了标靶放射性药物的精准度。这些成像技术能够即时监测放射性药物的分布和效应，从而将放射性药物精准地输送至病灶。这项发展对个人化医疗具有重要意义，个人化医疗可以根据影像学结果量身订做治疗方案，以最大限度地提高治疗效果。
生物技术-製药伙伴关係：生物技术公司与大型製药公司之间的策略伙伴关係正在加速靶向放射性药物的开发。例如，旨在开发用于癌症治疗的新型放射性标记抗体的合作正在拓展标靶治疗的潜力。此类合作促进了资源、专业知识和临床数据的共用，最终加速了创新放射性药物的商业化。
扩大放射性同位素产能：为了满足日益增长的靶向放射性药物需求，各公司正在扩大关键放射性同位素的产能，包括Technetium-99m、镏-177和碘-131。此次扩产旨在应对供应链挑战，并确保临床所需的同位素供应充足。随着製造技术的进步，放射性药物的生产成本预计将下降，使更多患者能够获得这些治疗。

这些关键进展正在透过改善治疗的可及性、有效性和精准度，彻底改变靶向放射性药物市场。 FDA 的核准、α粒子疗法的进步以及行业相关人员之间不断扩大的伙伴关係关係，正在创造新的成长机会。随着产能的不断扩大和新技术的涌现，靶向放射性药物市场有望持续创新，并在全球医疗保健领域发挥更重要的作用。

The future of the global targeted radiopharmaceutical market looks promising with opportunities in the targeted therapy and targeted diagnosis markets. The global targeted radiopharmaceutical market is expected to grow with a CAGR of 14.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cancer & cardiovascular disease and the growing aging population.

Lucintel forecasts that, within the type category, targeted therapeutic is expected to witness higher growth over the forecast period due to use radioactive substances to selectively target and treat cancer cells or other disease tissues.
Within the application category, targeted therapy is expected to witness the higher growth due to effective treatment of cancers such as prostate cancer, neuroendocrine tumors, and lymphoma.
In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market is influenced by several emerging trends, shaping its future growth. These trends include technological advancements, regulatory changes, and the increasing importance of personalized medicine. As the industry continues to evolve, these trends not only impact treatment efficacy but also the ways in which new products are brought to market and integrated into healthcare systems globally.

Increased Focus on Theranostics: Theranostics, the combination of diagnostic and therapeutic radiopharmaceuticals, is a rapidly growing trend. This approach allows for precise targeting of cancer cells with radioactive isotopes, enabling personalized treatment plans. The ability to diagnose and treat simultaneously enhances treatment efficacy and reduces side effects. This trend is particularly prominent in oncology, where radiopharmaceuticals like Pluvicto for prostate cancer and Lutetium-177 are being used for both imaging and therapy, driving significant market growth.
Integration of AI and Machine Learning: AI and machine learning are increasingly being applied to radiopharmaceutical development. These technologies help optimize the design of radiopharmaceuticals by predicting their effectiveness and toxicity profiles. AI-driven tools are also streamlining the radiopharmaceutical manufacturing process, reducing costs and improving precision. This integration is particularly valuable in identifying optimal dosages and patient-specific treatment regimens, ultimately advancing personalized medicine and reducing adverse effects associated with radiation therapy.
Expansion of Targeted Cancer Therapies: Cancer remains the primary therapeutic focus for targeted radiopharmaceuticals, with numerous developments aimed at improving treatment outcomes. The rise of radiopharmaceuticals for hard-to-treat cancers, such as neuroendocrine tumors, has expanded the market. Innovations like alpha-particle therapies, which deliver more localized radiation to cancer cells, are gaining attention. This expansion is supported by increasing cancer prevalence and the growing demand for more effective, less invasive treatments, positioning radiopharmaceuticals as key tools in oncology.
Regulatory Advancements and Approval Process: Regulatory bodies, particularly the FDA and EMA, are streamlining the approval process for radiopharmaceuticals, facilitating quicker market access for new treatments. The U.S. FDA, for example, has provided more flexible pathways for radiopharmaceutical approval, expediting the process for life-saving treatments. This trend is not only reducing the time from research to patient but also fostering innovation in radiopharmaceutical design. Stronger regulatory support is expected to enhance market confidence and further drive the adoption of these therapies globally.
Global Collaboration and Research Initiatives: Collaborative research efforts between countries and institutions are boosting radiopharmaceutical development. Public-private partnerships, such as those between universities, biotech companies, and healthcare organizations, are accelerating innovation. International research consortia are working on developing novel isotopes, improving production techniques, and enhancing the understanding of radiopharmaceuticals' effectiveness across different patient populations. This global approach is fostering a more diverse pipeline of radiopharmaceuticals, ensuring that patients worldwide benefit from cutting-edge treatments.

These trends are reshaping the targeted radiopharmaceutical market by driving innovation, improving patient outcomes, and reducing treatment costs. The convergence of AI, regulatory advancements, and global collaboration is accelerating the development and availability of targeted therapies, particularly in oncology. As the market grows, these trends will continue to optimize the delivery of personalized, precision-based treatments, ultimately transforming the healthcare landscape for cancer and other complex diseases.

Recent Developments in the Targeted Radiopharmaceutical Market

Several recent developments are transforming the targeted radiopharmaceutical market, from regulatory breakthroughs to technological innovations. These developments are enhancing the precision, availability, and effectiveness of radiopharmaceutical treatments, paving the way for improved patient outcomes and greater market growth.

FDA Approval of Pluvicto: The approval of Pluvicto (177Lu-PSMA-617) for prostate cancer represents a major milestone for targeted radiopharmaceuticals in oncology. This novel therapy combines a radioactive particle with a molecule that targets prostate cancer cells specifically, reducing damage to healthy tissues. The FDA's approval marks the first of its kind for prostate cancer, offering new hope for patients with advanced stages of the disease. This development opens the door for further innovations in cancer therapies, particularly for cancers with specific molecular targets.
Development of Alpha-Particle Therapies: Alpha-particle therapies, such as Actinium-225 and Radium-223, have emerged as promising treatments for various cancers. These therapies deliver highly localized radiation, minimizing damage to surrounding healthy tissue and providing a new approach for treating tumors that are resistant to traditional therapies. As research into alpha-particle therapy continues to evolve, the targeted radiopharmaceutical market is expected to see significant growth, especially in the treatment of metastatic cancers.
Technological Advancements in Imaging and Diagnostics: Advancements in molecular imaging technologies, such as PET and SPECT, have significantly improved the precision of targeted radiopharmaceuticals. These imaging techniques allow for real-time monitoring of the distribution and effectiveness of radiopharmaceuticals, ensuring that they are precisely targeted to the disease site. This development has major implications for personalized medicine, where treatments can be tailored based on the imaging results to maximize therapeutic outcomes.
Partnerships Between Biotech and Pharmaceutical Companies: Strategic partnerships between biotech firms and major pharmaceutical companies are accelerating the development of targeted radiopharmaceuticals. For instance, collaborations aimed at developing new radiolabeled antibodies for cancer therapy are pushing the boundaries of what is possible in targeted treatments. These alliances allow for sharing resources, expertise, and clinical data, ultimately speeding up the commercialization of innovative radiopharmaceuticals.
Expanding Production Capacity for Radioisotopes: To meet the growing demand for targeted radiopharmaceuticals, companies are expanding their production capabilities for key radioisotopes, such as Technetium-99m, Lutetium-177, and Iodine-131. This expansion is addressing supply chain challenges and ensuring that sufficient quantities of isotopes are available for clinical use. As production technologies improve, the cost of manufacturing radiopharmaceuticals is expected to decrease, making these therapies more accessible to a broader patient population.

These key developments are revolutionizing the targeted radiopharmaceutical market by improving the accessibility, effectiveness, and precision of treatments. The FDA approvals, advancements in alpha-particle therapies, and growing partnerships between industry players are creating new opportunities for growth. As production capabilities expand and new technologies emerge, the market is poised for continued innovation and a more significant role in global healthcare.

Strategic Growth Opportunities in the Targeted Radiopharmaceutical Market

Targeted radiopharmaceuticals offer significant growth opportunities across various applications. The market is evolving with an increasing focus on oncology, neurology, and diagnostic imaging, driven by both technological advancements and growing patient demand for more personalized treatments.

Oncology Treatments: Oncology is the largest application for targeted radiopharmaceuticals, and it continues to see the most significant growth. The development of radiopharmaceuticals targeting specific tumor types, such as Lutetium-177 for prostate cancer, is transforming cancer treatment by enabling targeted therapies that reduce damage to healthy tissue. With increasing cancer incidence, the market for radiopharmaceuticals in oncology is expected to expand rapidly, creating opportunities for both new entrants and established companies to innovate.
Neurology and Neurodegenerative Diseases: Targeted radiopharmaceuticals are increasingly being explored for neurological applications, particularly for neurodegenerative diseases like Alzheimer's. The development of PET radiopharmaceuticals to detect amyloid plaques is already making strides in diagnosis. As research progresses, there is potential for therapeutic radiopharmaceuticals that can target and treat these diseases at the molecular level. This expanding area offers new growth opportunities as the aging population increases globally.
Cardiology Applications: Radiopharmaceuticals are being developed for the diagnosis and treatment of cardiovascular diseases, such as atherosclerosis. For example, Thallium-201 is already used in cardiac imaging, but new developments are exploring radiopharmaceuticals for targeting heart tissue directly. As cardiovascular disease remains one of the leading causes of death worldwide, targeted radiopharmaceuticals offer significant potential for diagnostic imaging and therapy, especially in personalized treatment approaches.
Theranostic Applications: The combination of therapy and diagnostics into a single radiopharmaceutical, or theranostics, is gaining traction. By using the same agent for both diagnosis and treatment, theranostics allows for more personalized and precise interventions. This growing segment is driving innovations in oncology and other therapeutic areas, creating substantial growth opportunities as more personalized treatment regimens become available.
Expansion into Emerging Markets: Emerging markets, particularly in Asia and Latin America, are expected to see strong growth in the targeted radiopharmaceutical sector due to increasing healthcare investments and the rising incidence of cancer. As these markets develop their healthcare infrastructure, the demand for advanced therapies like targeted radiopharmaceuticals is expected to rise significantly. Companies entering these markets early can establish a competitive advantage by providing cost-effective solutions tailored to local healthcare needs.

These growth opportunities are transforming the targeted radiopharmaceutical market by expanding its application base and addressing diverse healthcare needs. From oncology to neurology and emerging markets, the opportunities for innovation and growth are vast. As these opportunities are realized, the market for targeted radiopharmaceuticals is poised to experience robust expansion across multiple therapeutic areas, benefiting patients globally.

Targeted Radiopharmaceutical Market Driver and Challenges

The targeted radiopharmaceutical market is shaped by a combination of technological advances, regulatory changes, economic factors, and market demand. However, these factors present both opportunities and challenges, requiring companies to adapt to evolving conditions while continuing to innovate in the development of new therapies. These drivers and challenges are interconnected and must be addressed to ensure the continued success of the market.

The factors responsible for driving the targeted radiopharmaceutical market include:

1. Technological Advancements: Recent technological innovations in imaging and radiopharmaceutical design are one of the major drivers of the market. Advances in PET and SPECT imaging technologies have enabled precise targeting and tracking of radiopharmaceuticals, ensuring higher treatment accuracy and lower side effects. New isotopes and alpha-particle therapies further expand the possibilities for treating cancer and other diseases. These advancements drive demand for more targeted and personalized treatment options.

2. Increasing Cancer Incidence: The global rise in cancer incidence is one of the key drivers behind the growth of the radiopharmaceutical market. As cancer rates continue to climb, especially in developed countries, the demand for more effective and less invasive treatments is accelerating. Targeted radiopharmaceuticals offer the potential to treat cancers more precisely, reducing side effects and improving outcomes, which makes them an attractive alternative to traditional therapies.

3. Regulatory Support and Approvals: The increasing support from regulatory bodies like the FDA and EMA is crucial in accelerating the adoption of targeted radiopharmaceuticals. Streamlined approval processes and flexible regulatory pathways are allowing new treatments to reach the market more quickly. This regulatory support is helping to drive innovation by encouraging pharmaceutical companies to invest more heavily in the development of novel radiopharmaceuticals.

4. Personalized Medicine Trends: The growing shift toward personalized medicine is a significant market driver. Radiopharmaceuticals allow for tailored treatments based on an individual's unique genetic profile, improving therapeutic outcomes. As precision medicine continues to gain traction, the demand for radiopharmaceuticals that can provide personalized, targeted treatment is expected to grow significantly.

5. Aging Global Population: The global aging population is contributing to increased demand for targeted radiopharmaceuticals, particularly for cancer and neurodegenerative diseases. Older individuals are more prone to conditions that can be treated with radiopharmaceuticals, driving market growth. This demographic shift is expected to continue expanding the patient base for targeted therapies.

Challenges in the targeted radiopharmaceutical market are:

1. High Costs of Production: One of the main challenges facing the market is the high cost of production for radiopharmaceuticals. Manufacturing these complex compounds, particularly the radioisotopes, requires specialized equipment and facilities, which can be expensive. Additionally, the costs of transporting and handling radioactive materials add to the overall expense, limiting access to these treatments in lower-income regions.

2. Limited Availability of Radioisotopes: The production of radioisotopes is often limited by availability and infrastructure. Short-lived isotopes require rapid and specialized manufacturing processes, which can lead to supply shortages. This issue is compounded by geopolitical factors, as the production of key isotopes like Technetium-99m is concentrated in a few regions, posing risks to global supply chains.

3. Regulatory Hurdles and Market Entry Barriers: Although regulatory support is generally improving, navigating the regulatory environment for new radiopharmaceuticals can still be challenging. Each country has its own set of regulations, and achieving international approval can be a time-consuming and expensive process. These hurdles can delay market entry and hinder the rapid commercialization of new radiopharmaceuticals.

The drivers such as technological advancements, increasing cancer rates, and regulatory support are propelling the market forward. However, challenges related to cost, supply limitations, and regulatory complexities must be addressed to ensure sustainable growth. Overcoming these obstacles will be critical for the widespread adoption of targeted radiopharmaceuticals in the future.

List of Targeted Radiopharmaceutical Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted radiopharmaceutical companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted radiopharmaceutical companies profiled in this report include-

Novartis
Bayer
Lantheus
Institute For Radioelements
Radiomedix
Curium Pharma
Clarity Pharmaceuticals

Targeted Radiopharmaceutical Market by Segment

The study includes a forecast for the global targeted radiopharmaceutical market by type, application, and region.

Targeted Radiopharmaceutical Market by Type [Value from 2019 to 2031]:

Targeted Therapeutic Radiopharmaceutical
Targeted Diagnostic Radiopharmaceutical

Targeted Radiopharmaceutical Market by Application [Value from 2019 to 2031]:

Targeted Therapy
Targeted Diagnosis

Targeted Radiopharmaceutical Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Targeted Radiopharmaceutical Market

The targeted radiopharmaceutical market has been rapidly evolving, with significant advancements in therapeutic and diagnostic radiopharmaceuticals. These compounds, which combine the precision of targeting specific disease sites with the power of radioactive isotopes, have gained momentum due to their ability to treat conditions like cancer with reduced side effects compared to traditional therapies. This sector is experiencing technological innovation, increased regulatory support, and growing healthcare demand. The United States, China, Germany, India, and Japan are key players driving these developments, each contributing to the global landscape with their unique approaches and market dynamics.

United States: The U.S. is a global leader in the targeted radiopharmaceutical market, with recent developments driven by increasing FDA approvals and technological advancements. Innovations such as the approval of Pluvicto (177Lu-PSMA-617) for prostate cancer therapy mark significant milestones. Investment in radiopharmaceuticals for oncology is expanding, with numerous clinical trials underway. Additionally, the U.S. is fostering research in theranostics, combining diagnostic and therapeutic properties in a single agent. Major pharmaceutical companies are focusing on developing advanced radiopharmaceuticals, leveraging AI and precision medicine to improve outcomes and reduce side effects.
China: China is rapidly emerging as a significant player in the targeted radiopharmaceutical market, supported by large-scale investments in both public and private sectors. The country's focus on oncology treatments is reflected in its growing number of clinical trials and regulatory approvals. In particular, China's state-run institutions and biotechnology firms are accelerating research into novel radiopharmaceuticals. The government's "Made in China 2025" initiative is pushing for innovation in the life sciences, which includes radiopharmaceutical production. Additionally, the Chinese healthcare system is embracing personalized medicine, which complements the development of targeted therapies, further driving growth.
Germany: Germany is home to several leading radiopharmaceutical companies and plays a pivotal role in Europe's radiopharmaceutical market. The country is focused on advancing its nuclear medicine capabilities, particularly in the field of cancer treatment. With a robust regulatory framework, Germany has facilitated the development of radiopharmaceuticals that are now being used in personalized treatments. Key institutions are collaborating on the development of radiopharmaceuticals for both diagnostic and therapeutic purposes, especially in the oncology field. Furthermore, Germany's strong research institutions are pushing boundaries in medical imaging and radioisotope production, which is propelling the market.
India: India has seen substantial growth in the targeted radiopharmaceutical sector, driven by an increasing demand for affordable cancer therapies. The country is establishing itself as a key hub for radiopharmaceutical production, particularly for diagnostic radiopharmaceuticals. With advancements in production technology, Indian companies are improving the availability of key isotopes like Technetium-99m. Research into new therapeutic applications for targeted radiopharmaceuticals, especially for cancer and neurological disorders, is gaining momentum. The government is also focused on strengthening the regulatory framework, making it easier for new treatments to enter the market and reach patients.
Japan: Japan remains a leader in the development of advanced targeted radiopharmaceuticals, particularly in nuclear medicine. Recent developments focus on integrating radiopharmaceuticals with diagnostic imaging to offer combined therapy options, a field known as theranostics. Japan's strong collaboration between academia, government, and industry fosters cutting-edge research and innovation. Notably, Japan has pioneered the development of radiopharmaceuticals for rare and complex cancers, such as neuroendocrine tumors. The country's highly advanced healthcare system and its regulatory approach support rapid adoption of new treatments, positioning Japan as a hub for radiopharmaceutical innovation in Asia.

Features of the Global Targeted Radiopharmaceutical Market

Market Size Estimates: Targeted radiopharmaceutical market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Targeted radiopharmaceutical market size by type, application, and region in terms of value ($B).
Regional Analysis: Targeted radiopharmaceutical market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted radiopharmaceutical market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted radiopharmaceutical market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the targeted radiopharmaceutical market by type (targeted therapeutic radiopharmaceutical and targeted diagnostic radiopharmaceutical), application (targeted therapy and targeted diagnosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Targeted Radiopharmaceutical Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Targeted Therapeutic Radiopharmaceutical: Trends and Forecast (2019-2031)
4.4 Targeted Diagnostic Radiopharmaceutical: Trends and Forecast (2019-2031)

5. Global Targeted Radiopharmaceutical Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Targeted Therapy: Trends and Forecast (2019-2031)
5.4 Targeted Diagnosis: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Targeted Radiopharmaceutical Market by Region

7. North American Targeted Radiopharmaceutical Market

7.1 Overview
7.4 United States Targeted Radiopharmaceutical Market
7.5 Mexican Targeted Radiopharmaceutical Market
7.6 Canadian Targeted Radiopharmaceutical Market

8. European Targeted Radiopharmaceutical Market

8.1 Overview
8.4 German Targeted Radiopharmaceutical Market
8.5 French Targeted Radiopharmaceutical Market
8.6 Spanish Targeted Radiopharmaceutical Market
8.7 Italian Targeted Radiopharmaceutical Market
8.8 United Kingdom Targeted Radiopharmaceutical Market

9. APAC Targeted Radiopharmaceutical Market

9.1 Overview
9.4 Japanese Targeted Radiopharmaceutical Market
9.5 Indian Targeted Radiopharmaceutical Market
9.6 Chinese Targeted Radiopharmaceutical Market
9.7 South Korean Targeted Radiopharmaceutical Market
9.8 Indonesian Targeted Radiopharmaceutical Market

10. ROW Targeted Radiopharmaceutical Market

10.1 Overview
10.4 Middle Eastern Targeted Radiopharmaceutical Market
10.5 South American Targeted Radiopharmaceutical Market
10.6 African Targeted Radiopharmaceutical Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Targeted Radiopharmaceutical Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Novartis
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Bayer
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Lantheus
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Institute For Radioelements
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Radiomedix
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Curium Pharma
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 Clarity Pharmaceuticals
- Company Overview
- Targeted Radiopharmaceutical Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Targeted Radiopharmaceutical Market
Figure 2.1: Usage of Targeted Radiopharmaceutical Market
Figure 2.2: Classification of the Global Targeted Radiopharmaceutical Market
Figure 2.3: Supply Chain of the Global Targeted Radiopharmaceutical Market
Figure 2.4: Driver and Challenges of the Targeted Radiopharmaceutical Market
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 4.1: Global Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Type
Figure 4.3: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Type
Figure 4.4: Trends and Forecast for Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2031)
Figure 4.5: Trends and Forecast for Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2031)
Figure 5.1: Global Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Application
Figure 5.3: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Application
Figure 5.4: Trends and Forecast for Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2019-2031)
Figure 5.5: Trends and Forecast for Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2019-2031)
Figure 6.1: Trends of the Global Targeted Radiopharmaceutical Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Targeted Radiopharmaceutical Market ($B) by Region (2025-2031)
Figure 7.1: Trends and Forecast for the North American Targeted Radiopharmaceutical Market (2019-2031)
Figure 7.2: North American Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
Figure 7.3: Trends of the North American Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
Figure 7.4: Forecast for the North American Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
Figure 7.5: North American Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
Figure 7.6: Trends of the North American Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
Figure 7.7: Forecast for the North American Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
Figure 7.8: Trends and Forecast for the United States Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Mexican Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 7.10: Trends and Forecast for the Canadian Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 8.1: Trends and Forecast for the European Targeted Radiopharmaceutical Market (2019-2031)
Figure 8.2: European Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
Figure 8.3: Trends of the European Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
Figure 8.4: Forecast for the European Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
Figure 8.5: European Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
Figure 8.6: Trends of the European Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
Figure 8.7: Forecast for the European Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
Figure 8.8: Trends and Forecast for the German Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the French Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Spanish Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the Italian Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 8.12: Trends and Forecast for the United Kingdom Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 9.1: Trends and Forecast for the APAC Targeted Radiopharmaceutical Market (2019-2031)
Figure 9.2: APAC Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
Figure 9.3: Trends of the APAC Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
Figure 9.4: Forecast for the APAC Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
Figure 9.5: APAC Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
Figure 9.6: Trends of the APAC Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
Figure 9.7: Forecast for the APAC Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
Figure 9.8: Trends and Forecast for the Japanese Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Indian Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the Chinese Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the South Korean Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 9.12: Trends and Forecast for the Indonesian Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 10.1: Trends and Forecast for the ROW Targeted Radiopharmaceutical Market (2019-2031)
Figure 10.2: ROW Targeted Radiopharmaceutical Market by Type in 2019, 2024, and 2031
Figure 10.3: Trends of the ROW Targeted Radiopharmaceutical Market ($B) by Type (2019-2024)
Figure 10.4: Forecast for the ROW Targeted Radiopharmaceutical Market ($B) by Type (2025-2031)
Figure 10.5: ROW Targeted Radiopharmaceutical Market by Application in 2019, 2024, and 2031
Figure 10.6: Trends of the ROW Targeted Radiopharmaceutical Market ($B) by Application (2019-2024)
Figure 10.7: Forecast for the ROW Targeted Radiopharmaceutical Market ($B) by Application (2025-2031)
Figure 10.8: Trends and Forecast for the Middle Eastern Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the South American Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 10.10: Trends and Forecast for the African Targeted Radiopharmaceutical Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Targeted Radiopharmaceutical Market
Figure 11.2: Market Share (%) of Top Players in the Global Targeted Radiopharmaceutical Market (2024)
Figure 12.1: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Type
Figure 12.2: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Application
Figure 12.3: Growth Opportunities for the Global Targeted Radiopharmaceutical Market by Region
Figure 12.4: Emerging Trends in the Global Targeted Radiopharmaceutical Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Targeted Radiopharmaceutical Market by Type and Application
Table 1.2: Attractiveness Analysis for the Targeted Radiopharmaceutical Market by Region
Table 1.3: Global Targeted Radiopharmaceutical Market Parameters and Attributes
Table 3.1: Trends of the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 3.2: Forecast for the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Targeted Radiopharmaceutical Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 4.4: Trends of Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 4.5: Forecast for Targeted Therapeutic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 4.6: Trends of Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 4.7: Forecast for Targeted Diagnostic Radiopharmaceutical in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Targeted Radiopharmaceutical Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 5.4: Trends of Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 5.5: Forecast for Targeted Therapy in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 5.6: Trends of Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 5.7: Forecast for Targeted Diagnosis in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Targeted Radiopharmaceutical Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Targeted Radiopharmaceutical Market (2025-2031)
Table 7.1: Trends of the North American Targeted Radiopharmaceutical Market (2019-2024)
Table 7.2: Forecast for the North American Targeted Radiopharmaceutical Market (2025-2031)
Table 7.3: Market Size and CAGR of Various Type in the North American Targeted Radiopharmaceutical Market (2019-2024)
Table 7.4: Market Size and CAGR of Various Type in the North American Targeted Radiopharmaceutical Market (2025-2031)
Table 7.5: Market Size and CAGR of Various Application in the North American Targeted Radiopharmaceutical Market (2019-2024)
Table 7.6: Market Size and CAGR of Various Application in the North American Targeted Radiopharmaceutical Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Targeted Radiopharmaceutical Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Targeted Radiopharmaceutical Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Targeted Radiopharmaceutical Market (2019-2031)
Table 8.1: Trends of the European Targeted Radiopharmaceutical Market (2019-2024)
Table 8.2: Forecast for the European Targeted Radiopharmaceutical Market (2025-2031)
Table 8.3: Market Size and CAGR of Various Type in the European Targeted Radiopharmaceutical Market (2019-2024)
Table 8.4: Market Size and CAGR of Various Type in the European Targeted Radiopharmaceutical Market (2025-2031)
Table 8.5: Market Size and CAGR of Various Application in the European Targeted Radiopharmaceutical Market (2019-2024)
Table 8.6: Market Size and CAGR of Various Application in the European Targeted Radiopharmaceutical Market (2025-2031)
Table 8.7: Trends and Forecast for the German Targeted Radiopharmaceutical Market (2019-2031)
Table 8.8: Trends and Forecast for the French Targeted Radiopharmaceutical Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Targeted Radiopharmaceutical Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Targeted Radiopharmaceutical Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Targeted Radiopharmaceutical Market (2019-2031)
Table 9.1: Trends of the APAC Targeted Radiopharmaceutical Market (2019-2024)
Table 9.2: Forecast for the APAC Targeted Radiopharmaceutical Market (2025-2031)
Table 9.3: Market Size and CAGR of Various Type in the APAC Targeted Radiopharmaceutical Market (2019-2024)
Table 9.4: Market Size and CAGR of Various Type in the APAC Targeted Radiopharmaceutical Market (2025-2031)
Table 9.5: Market Size and CAGR of Various Application in the APAC Targeted Radiopharmaceutical Market (2019-2024)
Table 9.6: Market Size and CAGR of Various Application in the APAC Targeted Radiopharmaceutical Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Targeted Radiopharmaceutical Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Targeted Radiopharmaceutical Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Targeted Radiopharmaceutical Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Targeted Radiopharmaceutical Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Targeted Radiopharmaceutical Market (2019-2031)
Table 10.1: Trends of the ROW Targeted Radiopharmaceutical Market (2019-2024)
Table 10.2: Forecast for the ROW Targeted Radiopharmaceutical Market (2025-2031)
Table 10.3: Market Size and CAGR of Various Type in the ROW Targeted Radiopharmaceutical Market (2019-2024)
Table 10.4: Market Size and CAGR of Various Type in the ROW Targeted Radiopharmaceutical Market (2025-2031)
Table 10.5: Market Size and CAGR of Various Application in the ROW Targeted Radiopharmaceutical Market (2019-2024)
Table 10.6: Market Size and CAGR of Various Application in the ROW Targeted Radiopharmaceutical Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Targeted Radiopharmaceutical Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Targeted Radiopharmaceutical Market (2019-2031)
Table 10.9: Trends and Forecast for the African Targeted Radiopharmaceutical Market (2019-2031)
Table 11.1: Product Mapping of Targeted Radiopharmaceutical Suppliers Based on Segments
Table 11.2: Operational Integration of Targeted Radiopharmaceutical Manufacturers
Table 11.3: Rankings of Suppliers Based on Targeted Radiopharmaceutical Revenue
Table 12.1: New Product Launches by Major Targeted Radiopharmaceutical Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Targeted Radiopharmaceutical Market

02-2729-4219

+886-2-2729-4219

License/价格

标靶放射性药物市场报告：2031 年趋势、预测与竞争分析

Targeted Radiopharmaceutical Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章市场概况

第三章：市场趋势及预测分析

4. 全球标靶放射性药物市场（按类型）

5. 全球标靶放射性药物市场（依应用）

第六章区域分析

7. 北美标靶放射性药物市场

8. 欧洲目标放射性药物市场

9. 亚太地区标靶放射性药物市场

10. 其他地区针对放射性药物市场

第11章竞争分析

第十二章：机会与策略分析

第十三章价值链主要企业的公司简介

第十四章附录

Targeted Radiopharmaceutical Market by Type [Value from 2019 to 2031]:

Targeted Radiopharmaceutical Market by Application [Value from 2019 to 2031]:

Targeted Radiopharmaceutical Market by Region [Value from 2019 to 2031]:

This report answers following 11 key questions: